Glaser Weil Advises INVO Bioscience in Merger with NAYA Biosciences

Glaser Weil represented INVO Bioscience, Inc. (Nasdaq: INVO), a global leader in expanding access to advanced fertility treatment, in its definitive merger agreement with NAYA Biosciences Inc., a privately-held company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine.

The transaction—an all-stock merger—will allow NAYA to expand INVO's footprint of fertility clinic operations across the United States as well as advance the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.

The deal closed on October 11, 2024, and was jointly announced on October 14, 2024. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the “NAYA” ticker.

The Glaser Weil corporate team was led by Partner Marc Indeglia and associates Josephine Wu and Gabriel Kiss.